SCHEMBL22717411

SCHEMBL22717411

C=C(OCC)c1cc(-c2ccccc2OC)c(C(=O)OCC)cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRP O00591 2/20 0.49
▸ GABRD O14764 2/20 0.49
▸ GABRA1 P14867 2/20 0.49
▸ GABRB1 P18505 2/20 0.49
▸ GABRG2 P18507 2/20 0.49
▸ GABRB3 P28472 2/20 0.49
▸ GABRA5 P31644 2/20 0.49
▸ GABRA3 P34903 2/20 0.49
▸ GABRA2 P47869 2/20 0.49
▸ GABRB2 P47870 2/20 0.49
▸ GABRA4 P48169 2/20 0.49
▸ GABRE P78334 2/20 0.49
▸ GABRA6 Q16445 2/20 0.49
▸ GABRG1 Q8N1C3 2/20 0.49
▸ GABRG3 Q99928 2/20 0.49
▸ GABRQ Q9UN88 2/20 0.49
▸ LMNA P02545 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22717520 0.88 GABRP (0.51) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL22717380 0.82 KDM4E (0.50) LMNATP53MAPTMEN1KMT2A
SCHEMBL22717735 0.82 DPP4 (0.49) LMNATP53MAPTMEN1KMT2A
SCHEMBL30898516 0.82 KDM4E (0.50) LMNATP53MAPTMEN1KMT2A
SCHEMBL22717307 0.82 LMNA (0.46) LMNATP53MAPTMEN1KMT2A
SCHEMBL22717257 0.81 MAPT (0.47) LMNATP53MAPTMEN1KMT2A
SCHEMBL22717419 0.81 DPP4 (0.53) LMNATP53MAPTDPP4
SCHEMBL25309295 0.80 NPSR1 (0.48) LMNATP53MAPTMEN1KMT2A
SCHEMBL22717826 0.80 MAPT (0.48) LMNATP53MAPTMEN1KMT2A
SCHEMBL25153682 0.79 LMNA (0.45) LMNATP53MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049074-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. (US) 2026-02-19 — — US disclosed
US-12509454-B2 Thiadiazolyl derivatives IDEAYA BIOSCIENCES, INC. (US) 2025-12-30 — — US disclosed
EP-3976608-B1 THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES INC (US) 2023-11-08 — — EP disclosed
EP-3976608-B1 THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES INC (US) 2023-11-08 — — EP disclosed
US-20230078112-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. 2023-03-16 — — US disclosed
EP-3976608-A1 THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS Ideaya Biosciences, Inc. (US) 2022-04-06 — — EP disclosed
CN-114127062-A Thiadiazolyl derivatives as inhibitors of DNA polymerase Theta 伊迪亚生物科学有限公司 2022-03-01 — — CN disclosed
WO-2020243459-A1 THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-12-03 — — WO disclosed
WO-2020243459-A1 THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049074-A1 THIADIAZOLYL DERIVATIVES POLH, POLM, POLD1 GABRP 930/4885GABRD 286/4885GABRA1 1398/4885
US-20230078112-A1 THIADIAZOLYL DERIVATIVES POLQ, POLK, POLA1 GABRP 1764/4885GABRD 989/4885GABRA1 3313/4885
US-12509454-B2 Thiadiazolyl derivatives POLD1, POLQ, DNA2 GABRP 3209/4885GABRD 1498/4885GABRA1 4384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback